Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis
Dermatology Reports · 30.01.2026 · 18 (4)
DOI: 10.4081/dr.2026.10240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Reports, online erschienen am 30.01.2026. Verfasst von Davide Bertolla und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We report the case of a 50-year-old woman with severe palmoplantar psoriasis who developed alopecia areata (AA) 2 months after initiating treatment with tildrakizumab (100 mg subcutaneously). The patient had no personal or familial history of autoimmune disorders, and the diagnosis of AA was confirmed by clinical and trichoscopic evaluation. Tildrakizumab was discontinued, and the patient was treated with topical corticosteroids and low-dose oral methylprednisolone, achieving complete hair regrowth within 6 months. Psoriasis subsequently recurred, and treatment was successfully switched to bimekizumab, with sustained remission and no adverse events. To the best of our knowledge, published reports of new-onset AA during tildrakizumab therapy for psoriasis are lacking. The temporal correlation, lack of confounding risk factors, and resolution upon drug withdrawal suggest a causal relationship. This case expands the spectrum of paradoxical reactions (PRs) to biologic therapies and highlights the need for vigilance regarding autoimmune manifestations during interleukin (IL)-23 inhibition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara.
- Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini.
Zitieren
APA
Bertolla, D., & Conti, A. (2026). Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis. Dermatology Reports, 18(4). https://doi.org/10.4081/dr.2026.10240
Vancouver
Bertolla D, Conti A. Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis. Dermatology Reports. 2026;18(4). doi:10.4081/dr.2026.10240
BibTeX
@article{Bertolla2026,
author = {Bertolla, Davide and Conti, Andrea},
title = {Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis},
journal = {Dermatology Reports},
year = {2026},
volume = {18},
number = {4},
doi = {10.4081/dr.2026.10240}
}
EUVIMED